Used as an anticancer agent targeting tumors with specific genetic alterations involving NTRK gene fusions and ROS1 rearrangements. It is effective in treating solid tumors that have spread or cannot be surgically removed, especially in non-small cell lung cancer and neuroblastoma. Works by inhibiting abnormal tyrosine kinases that drive uncontrolled cell growth. Shows activity in central nervous system tumors due to its ability to cross the blood-brain barrier, making it suitable for cancers with brain metastases. Administered orally, it offers a targeted therapy option for patients with advanced or refractory cancers harboring these molecular markers.